JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 102 filers reported holding JUNO THERAPEUTICS INC in Q4 2014. The put-call ratio across all filers is - and the average weighting 1.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $7,762,000 | +272.6% | 169,809 | +265.7% | 0.00% | +200.0% |
| Q3 2017 | $2,083,000 | +31.5% | 46,435 | -12.4% | 0.00% | – |
| Q2 2017 | $1,584,000 | +33.8% | 52,994 | -0.7% | 0.00% | – |
| Q1 2017 | $1,184,000 | +239.3% | 53,346 | +188.4% | 0.00% | – |
| Q4 2016 | $349,000 | +24.2% | 18,500 | +97.2% | 0.00% | – |
| Q3 2016 | $281,000 | +1.1% | 9,380 | +29.9% | 0.00% | – |
| Q2 2016 | $278,000 | -49.2% | 7,222 | -49.7% | 0.00% | – |
| Q1 2016 | $547,000 | +26.0% | 14,366 | +45.4% | 0.00% | – |
| Q4 2015 | $434,000 | -10.0% | 9,877 | -16.5% | 0.00% | – |
| Q3 2015 | $482,000 | -16.9% | 11,835 | +8.9% | 0.00% | – |
| Q2 2015 | $580,000 | +199.0% | 10,871 | +239.3% | 0.00% | – |
| Q1 2015 | $194,000 | -97.5% | 3,204 | -97.9% | 0.00% | -100.0% |
| Q4 2014 | $7,833,000 | – | 150,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Biomark Capital Management Co. LLC | 2,168,601 | $65,080,000 | 86.12% |
| Crestline Management, LP | 17,348,799 | $520,637,000 | 66.02% |
| Omega Fund Management, LLC | 1,229,512 | $36,898,000 | 28.17% |
| SIB LLC | 100,000 | $3,001,000 | 2.42% |
| Clarius Group, LLC | 117,896 | $3,538,000 | 1.65% |
| BB BIOTECH AG | 1,405,000 | $42,164,000 | 1.48% |
| Duquesne Family Office | 493,000 | $14,795,000 | 1.31% |
| First Washington CORP | 65,320 | $1,960,000 | 1.10% |
| PFM Health Sciences, LP | 1,124,285 | $33,740,000 | 0.99% |
| Partner Investment Management, L.P. | 18,376 | $551,000 | 0.82% |